David Roblin

David Roblin is vice president, clinical R&D head at Pfizer Europe.


A Critical Juncture for Antibiotic R&D

With little momentum in developing new new antibiotics to fight antimicrobial resistance, the time is now to emphasize "push" and "pull" incentives and demonstrate how innovation in this area will lead to patient benefit and economic reward.

Need for Innovation in Antibiotic Development, Before It’s Too Late

There is a lack of push in the development of new antibiotics while anti-microbial resistance is a priority topic in healthcare policy and on the political agenda.